Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)

v3.21.2
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 31, 2010
contingent_value_right
contingent_value_right_series
Jun. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Number of CVR Series | contingent_value_right_series 4      
Transferred over Time | Phase 3 Clinical Trial        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Gross contract asset   $ 10,000,000 $ 10,000,000  
Maximum | Transferred over Time | Development, Regulatory, & Commercial Milestones and Tiered Royalties        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Investments   375,000,000 375,000,000  
Metabasis        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Number of CVRs issued per acquiree share | contingent_value_right 4      
Number of CVRs issued from each CVR series | contingent_value_right 1      
Frequency of cash payments to CVR holders 6 months      
Contingent liabilities - Icagen        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Payment for contingent consideration liabilities     1,100,000  
Contingent liabilities - Pfenex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Reduction in contingent liability   34,100,000 33,800,000  
Recurring        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   279,972,000 279,972,000 $ 363,567,000
Liabilities, fair value   14,802,000 14,802,000 49,193,000
Recurring | Contingent liabilities - Crystal        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   800,000 800,000 800,000
Recurring | Contingent liabilities - CyDex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   376,000 376,000 508,000
Recurring | Contingent liabilities - Metabasis        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   3,930,000 3,930,000 3,821,000
Recurring | Contingent liabilities - Icagen        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   5,625,000 5,625,000 6,404,000
Recurring | Contingent liabilities - Pfenex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   3,800,000 3,800,000 37,600,000
Recurring | Contingent liabilities - xCella        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   240,000 240,000 0
Recurring | Amounts owed to former licensor        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   31,000 31,000 60,000
Recurring | Short-term investments        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   239,749,000 239,749,000 324,478,000
Recurring | Investment in Viking common stock        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   40,223,000 40,223,000 32,763,000
Recurring | Investment in warrants        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   0 0 6,326,000
Recurring | Level 1        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   45,892,000 45,892,000 42,527,000
Liabilities, fair value   31,000 31,000 60,000
Recurring | Level 1 | Contingent liabilities - Crystal        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   0 0 0
Recurring | Level 1 | Contingent liabilities - CyDex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   0 0 0
Recurring | Level 1 | Contingent liabilities - Metabasis        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   0 0 0
Recurring | Level 1 | Contingent liabilities - Icagen        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   0 0 0
Recurring | Level 1 | Contingent liabilities - Pfenex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   0 0 0
Recurring | Level 1 | Contingent liabilities - xCella        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   0 0 0
Recurring | Level 1 | Amounts owed to former licensor        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   31,000 31,000 60,000
Recurring | Level 1 | Short-term investments        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   5,669,000 5,669,000 3,438,000
Recurring | Level 1 | Investment in Viking common stock        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   40,223,000 40,223,000 32,763,000
Recurring | Level 1 | Investment in warrants        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   0 0 6,326,000
Recurring | Level 2        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   233,368,000 233,368,000 320,647,000
Liabilities, fair value   3,930,000 3,930,000 3,821,000
Recurring | Level 2 | Contingent liabilities - Crystal        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   0 0 0
Recurring | Level 2 | Contingent liabilities - CyDex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   0 0 0
Recurring | Level 2 | Contingent liabilities - Metabasis        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   3,930,000 3,930,000 3,821,000
Recurring | Level 2 | Contingent liabilities - Icagen        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   0 0 0
Recurring | Level 2 | Contingent liabilities - Pfenex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   0 0 0
Recurring | Level 2 | Contingent liabilities - xCella        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   0 0 0
Recurring | Level 2 | Amounts owed to former licensor        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   0 0 0
Recurring | Level 2 | Short-term investments        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   233,368,000 233,368,000 320,647,000
Recurring | Level 2 | Investment in Viking common stock        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   0 0 0
Recurring | Level 2 | Investment in warrants        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   0 0 0
Recurring | Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   712,000 712,000 393,000
Liabilities, fair value   10,841,000 10,841,000 45,312,000
Recurring | Level 3 | Contingent liabilities - Crystal        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   800,000 800,000 800,000
Recurring | Level 3 | Contingent liabilities - CyDex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   376,000 376,000 508,000
Recurring | Level 3 | Contingent liabilities - Metabasis        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   0 0 0
Recurring | Level 3 | Contingent liabilities - Icagen        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   5,625,000 5,625,000 6,404,000
Recurring | Level 3 | Contingent liabilities - Pfenex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   3,800,000 3,800,000 37,600,000
Recurring | Level 3 | Contingent liabilities - xCella        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   240,000 240,000 0
Recurring | Level 3 | Amounts owed to former licensor        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Liabilities, fair value   0 0 0
Recurring | Level 3 | Short-term investments        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   712,000 712,000 393,000
Recurring | Level 3 | Investment in Viking common stock        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   0 0 0
Recurring | Level 3 | Investment in warrants        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Assets, fair value   $ 0 $ 0 $ 0